The Relationship between Vitamin D Deficiency and Pulmonary Hypertension

Demir, Mehmet; Uyan, Umut; Keçeoçlu, S.; Demir, Canan

doi:10.14712/23362936.2014.17

Cited by 34 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding pulmonary hypertension, Demir et al [89] estimated that there is a statistically significant difference p < 0.001) in the systolic pulmonary artery pressure in patients with low levels of vitamin D (36.31 ± 8.99 mmHg) and those with adequate serum levels (32.42 ± 8.06 mmHg). This promising result notwithstanding, currently there is not enough evidence to correlate pulmonary hypertension and vitamin D levels abnormalities.…”

Section: Methodsmentioning

confidence: 99%

Vitamin D and its effects on cardiovascular diseases: a comprehensive review

Pérez-Hernández

Aptilon-Duque

Nostroza-Hernández

et al. 2016

Korean J Intern Med

View full text Add to dashboard Cite

Vitamin D is a molecule that is actively involved in multiple metabolic pathways. It is mostly known for its implications related to calcium metabolism. It has also been determined that it actively participates in the cardiovascular system, influencing blood pressure, coronary artery disease and other vascular diseases, such as heart failure and atrial fibrillation. Furthermore, it has been established that this vitamin is extensively involved in the regulation of both the renin angiotensin aldosterone system and the immune system. In this review, we present the different vitamin D metabolic pathways associated with the cardiovascular pathophysiology, and we include studies in animal and human models, as well as some of the controversies found in the literature. This review also incorporates an overview of the implications in the molecular biology and public health fields.

show abstract

Section: Methodsmentioning

confidence: 99%

Vitamin D and its effects on cardiovascular diseases: a comprehensive review

Pérez-Hernández

Aptilon-Duque

Nostroza-Hernández

et al. 2016

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…Therefore, low vitamin D status in PAH patients could be the reason for the elevated PTH. Later, epidemiological studies demonstrated that vitamin D deficiency is quite prevalent in PAH patients [59,62,63]. In the prospective study carried out by Demir et al, PAH patients presented much lower vitamin D levels (median of 6.79 ng/mL), considered as severe deficit of vitamin D (<10 ng/mL of serum 25(OH)D 3 ), than controls (18.76 ng/mL) [62].…”

Section: Vitamin Dmentioning

confidence: 99%

Impact of Nutrition on Pulmonary Arterial Hypertension

et al. 2020

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is characterized by sustained vasoconstriction, vascular remodeling, inflammation, and in situ thrombosis. Although there have been important advances in the knowledge of the pathophysiology of PAH, it remains a debilitating, limiting, and rapidly progressive disease. Vitamin D and iron deficiency are worldwide health problems of pandemic proportions. Notably, these nutritional alterations are largely more prevalent in PAH patients than in the general population and there are several pieces of evidence suggesting that they may trigger or aggravate disease progression. There are also several case reports associating scurvy, due to severe vitamin C deficiency, with PAH. Flavonoids such as quercetin, isoflavonoids such as genistein, and other dietary polyphenols including resveratrol slow the progression of the disease in animal models of PAH. Finally, the role of the gut microbiota and its interplay with the diet, host immune system, and energy metabolism is emerging in multiple cardiovascular diseases. The alteration of the gut microbiota has also been reported in animal models of PAH. It is thus possible that in the near future interventions targeting the nutritional status and the gut dysbiosis will improve the outcome of these patients.

show abstract

“…Some preliminary evidence suggests that vitD deficiency is common in PAH [23][24][25][26]. Herein, we aimed to examine the total, bioavailable, and free 25(OH)vitD levels and their relationship with relevant clinical variables in PAH.…”

Section: Introductionmentioning

confidence: 99%

Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension

Callejo

Mondéjar-Parreño

Esquivel-Ruiz

et al. 2020

JCM

View full text Add to dashboard Cite

Introduction: Epidemiological studies suggest a relationship between vitamin D deficiency and cardiovascular and respiratory diseases. However, whether total, bioavailable, and/or free vitamin D levels have a prognostic role in pulmonary arterial hypertension (PAH) is unknown. We aimed to determine total, bioavailable, and free 25-hydroxy-vitamin D (25(OH)vitD) plasma levels and their prognostic value in PAH patients. Methods: In total, 67 samples of plasma from Spanish patients with idiopathic, heritable, or drug-induced PAH were obtained from the Spanish PH Biobank and compared to a cohort of 100 healthy subjects. Clinical parameters were obtained from the Spanish Registry of PAH (REHAP). Results: Seventy percent of PAH patients had severe vitamin D deficiency (total 25(OH)vitD < 10 ng/mL) and secondary hyperparathyroidism. PAH patients with total 25(OH)vitD plasma above the median of this cohort (7.17 ng/mL) had better functional class and higher 6-min walking distance and TAPSE (tricuspid annular plane systolic excursion). The main outcome measure of survival was significantly increased in these patients (age-adjusted hazard ratio: 5.40 (95% confidence interval: 2.88 to 10.12)). Vitamin D-binding protein (DBP) and albumin plasma levels were downregulated in PAH. Bioavailable 25(OH)vitD was decreased in PAH patients compared to the control cohort. Lower levels of bioavailable 25(OH)vitD (<0.91 ng/mL) were associated with more advanced functional class, lower exercise capacity, and higher risk of mortality. Free 25(OH)vitD did not change in PAH; however, lower free 25(OH)vitD (<1.53 pg/mL) values were also associated with high risk of mortality. Conclusions: Vitamin D deficiency is highly prevalent in PAH, and low levels of total 25(OH)vitD were associated with poor prognosis.

show abstract

The Relationship between Vitamin D Deficiency and Pulmonary Hypertension

Cited by 34 publications

References 17 publications

Vitamin D and its effects on cardiovascular diseases: a comprehensive review

Vitamin D and its effects on cardiovascular diseases: a comprehensive review

Impact of Nutrition on Pulmonary Arterial Hypertension

Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About